Brief: Invivyd Announces Additional Positive Initial Data From Ongoing Phase 1 Clinical Trial Of Vyd222
17/07/2023 12:02
July 17 (Reuters) - Invivyd Inc IVVD.O :
* INVIVYD ANNOUNCES ADDITIONAL POSITIVE INITIAL DATA FROM
ONGOING
PHASE 1 CLINICAL TRIAL OF VYD222, A MONOCLONAL ANTIBODY
CANDIDATE IN DEVELOPMENT FOR THE PREVENTION OF SYMPTOMATIC
COVID-19 IN IMMUNOCOMPROMISED PEOPLE
* INVIVYD INC - CONTINUED FAVORABLE SAFETY AND TOLERABILITY
PROFILE FOR ALL DOSE LEVELS TESTED
* INVIVYD- ONGOING ANALYSIS OF SERUM NEUTRALIZING ACTIVITY,
PHARMACOKINETIC DATA EXPECTED TO SUPPORT RAPID ANTICIPATED
TRANSITION TO PIVOTAL CLINICAL TRIAL
Source text for Eikon: ID:nGNX3pHzt1
Further company coverage: IVVD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview